Evaluating the Safety, Tolerance, and Pharmacokinetics of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in Children Infected With HIV and TB

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by National Institute of Allergy and Infectious Diseases (NIAID)
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT01751568
First received: December 14, 2012
Last updated: June 28, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: May 2019 (Final data collection date for primary outcome measure)